pharmazz

Diabetic Ketoacidosis

PMZ-2123 prevents the development of neurological complications in diabetic ketoacidosis patients.

Intravenous administration of PMZ-2123 prevents the development of cerebral edema in patients of diabetic ketoacidosis. Efficacy has been demonstrated in animal models of diabetic ketoacidosis.

Patents issued in United States, Japan, European Union, Australia, China and Canada.

PMZ-2123 has been safely used in humans as an investigational agent (NCT00115583; NCT00915070; NCT01658410).

Status of Diabetic Ketoacidosis

Product
Pre-Clinical
Clinical

phase 1

phase 2

phase 3

market

Diabetic Ketoacidosis (PMZ-2123)

..

Publications

  • Gulati, A., Lavhale, M., Marwah, B., Khandelwal, S., and Havalad, S. (2014) ETA receptor antagonist, BQ123, in the treatment of Diabetic Ketoacidosis. Basic Clin Pharmacol 115, 240-240
  • Havalad, V., Gulati, A., Swanson, E., Briyal, S., Ghai, K., Heneghan, M.K., Havalad, S. (2013) Diabetic children with DKA have elevated Endothelin-1 levels. Pediatric Academic Societies EPAS2013:2910.100
  • Gulati, A., Lavhale, M., and Havalad, S. (2013) BQ123, An ETA receptor antagonist, in the treatment of Diabetic Ketoacidosis. Crit Care Med 41
    Read more
  • Gulati, A., Lavhale, M., Marwah, B., and Havalad, S. (2013) ETA receptor antagonists in the treatment of diabetic ketoacidosis. Life Sciences 93, e73
    Read more
  • Gulati, A., Lavhale, M. S., Koenig, K., and Havalad, S. (2009) ET receptor antagonist in the treatment of Diabetic Ketoacidosis. J Clin Pharmacol 49, 1125